(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously ...

The board of directors of (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

These blue chip dividend stocks would be ideal for investors who had to hold them forever. They provide reliable streams of ...

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...

Born in 1970 in Gwangju, South Korea, Kang hails from a literary family, with her father being a respected novelist.

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

Peddock Capital Advisors LLC lowered its position in Mastercard Incorporated (NYSE:MA – Free Report) by 1.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often ...